Back

Aspirin for the Primary Prevention of Cardiovascular Disease – Represented in NEJM by the ASPREE and ASCEND trials (and in Lancet by the ARRIVE trial).

1 September 2019 (11:23 - 11:46)
Organised by:
Congress Presentation Part of: Highlights from the New England Journal of Medicine: editors’ choice European Society of Cardiology ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor John Mcneil

Monash University, Melbourne (Australia)

2 More presentations in this session

Presentation thumbnail
Novel Therapeutic Agents for Transthyretin Amyloidosis – Represented in NEJM by the ATTR-ACT, APOLLO, and NEURO-TTR trials.
Professor C. Rapezzi (Ferrara, IT)
Slides Video
Presentation thumbnail
Transcatheter Aortic Valve Replacement in Low-Risk Patients – Represented in NEJM by the PARTNER 3 and Evolut Low Risk trials.
Doctor M. Mack (Dallas, US)
Slides Video

Access the full session

Session thumbnail
Highlights from the New England Journal of Medicine: editors’ choice

The Event

Event poster

ESC Congress 2019

1 September 2019 11:23 CET
You may be interested in
thumbnail
Congress Session
The EHJ’s year in cardiovascular medicine: cardio-oncology, heart failure, and arrhythmias
thumbnail
ESC TV Today
Episode 4: Heart disease in dialysis patients - Substance abuse and heart disease
thumbnail
ESC TV Today
Episode 12: Relevance and management of ventricular ectopic beats - Lp(a) in cardiovascular risk management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources